CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Xeris Biopharma Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Xeris Biopharma Holdings Inc
1375 West Fulton Street, Suite 1300
Phone: (302) 658-7581p:302 658-7581 CHICAGO, IL  60607  United States Ticker: XERSXERS
Business Summary
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Marla S.Persky 68 8/1/2024 4/1/2018
President, Chief Operating Officer KevinMcCulloch 61 8/1/2024 8/1/2024
Chief Executive Officer, Director John P.Shannon 62 8/1/2024 2/1/2017
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Strongbridge Biopharma plc 900 Northbrook Dr Ste 200 TREVOSE PA United States
Cortendo AB 900 Northbrook Drive Trevose PA United States

Business Names
Business Name
Cortendo AB
Strongbridge Biopharma Limited
Strongbridge Biopharma plc
Strongbridge Dublin Limited
Xeris Pharmaceuticals Australia Pty Ltd
XERS

General Information
Number of Employees: 377 (As of 12/31/2023)
Outstanding Shares: 149,081,461 (As of 10/31/2024)
Shareholders: 225
Stock Exchange: NASD
Federal Tax Id: 203352427
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024